Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis
| Autor: | Michelle Magid, Christopher Sinke, M. Axel Wollmer, Tillmann H.C. Kruger, Eric Finzi, Insa Neumann, Jara Schulze |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Placebo complex mixtures law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Neurotoxin Botulinum Toxins Type A Biological Psychiatry Depression (differential diagnoses) Depression business.industry Botulinum toxin Skin Aging 030227 psychiatry Affect Psychiatry and Mental health Treatment Outcome Mood Neuromuscular Agents Meta-analysis business 030217 neurology & neurosurgery Management of depression medicine.drug |
| Zdroj: | Journal of Psychiatric Research. 135:332-340 |
| ISSN: | 0022-3956 |
| DOI: | 10.1016/j.jpsychires.2021.01.016 |
| Popis: | Botulinum toxin (BTX) treatment of glabellar frown lines is one of the most common procedures in aesthetic medicine. In addition to its cosmetic effect, the neurotoxin has been shown to have a positive influence on mood and affect. Several randomized clinical trials (RCTs) have examined the effect of botulinum toxin on the treatment of depression. Combining the results of the five RCTs in a random effects meta-analysis revealed that patients treated with BTX showed a more intense improvement of depressive symptoms in comparison to subjects that received placebo injections (d = 0.98). Despite methodological limitations, the results of this study emphasize the effectiveness of BTX in the treatment of depression and therefore pave the way for its use in the field of psychiatry. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect